このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

2015年3月4日 更新者:Pfizer

12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)

To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder

調査の概要

研究の種類

介入

入学 (実際)

1712

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Homewood、Alabama、アメリカ、35209
        • Pfizer Investigational Site
      • Huntsville、Alabama、アメリカ、35801
        • Pfizer Investigational Site
      • Mobile、Alabama、アメリカ、36608
        • Pfizer Investigational Site
    • California
      • Carmichael、California、アメリカ、95608
        • Pfizer Investigational Site
      • Orangevale、California、アメリカ、95662
        • Pfizer Investigational Site
      • San Diego、California、アメリカ、92103-6204
        • Pfizer Investigational Site
    • Colorado
      • Aurora、Colorado、アメリカ、80012
        • Pfizer Investigational Site
    • Connecticut
      • Waterbury、Connecticut、アメリカ、06708
        • Pfizer Investigational Site
    • Florida
      • Miami、Florida、アメリカ、33186
        • Pfizer Investigational Site
      • Wellington、Florida、アメリカ、33414
        • Pfizer Investigational Site
    • Georgia
      • Atlanta、Georgia、アメリカ、30342
        • Pfizer Investigational Site
    • Idaho
      • Coeur D Alene、Idaho、アメリカ、83814
        • Pfizer Investigational Site
      • Sandpoint、Idaho、アメリカ、83864
        • Pfizer Investigational Site
    • Illinois
      • Aurora、Illinois、アメリカ、60504
        • Pfizer Investigational Site
    • Iowa
      • West Des Moines、Iowa、アメリカ、50266
        • Pfizer Investigational Site
    • Kansas
      • Newton、Kansas、アメリカ、67114
        • Pfizer Investigational Site
    • Louisiana
      • Shrevport、Louisiana、アメリカ、71106
        • Pfizer Investigational Site
    • Massachusetts
      • Watertown、Massachusetts、アメリカ、02472
        • Pfizer Investigational Site
    • Minnesota
      • Chaska、Minnesota、アメリカ、55318
        • Pfizer Investigational Site
    • New Jersey
      • Lawrenceville、New Jersey、アメリカ、08648
        • Pfizer Investigational Site
    • New Mexico
      • Albuquerque、New Mexico、アメリカ、87109
        • Pfizer Investigational Site
    • New York
      • Garden City、New York、アメリカ、11530
        • Pfizer Investigational Site
      • Mineola、New York、アメリカ、11501
        • Pfizer Investigational Site
    • North Carolina
      • Burlington、North Carolina、アメリカ、27215
        • Pfizer Investigational Site
      • Concord、North Carolina、アメリカ、28025
        • Pfizer Investigational Site
      • Huntersville、North Carolina、アメリカ、28078
        • Pfizer Investigational Site
    • Ohio
      • Dayton、Ohio、アメリカ、45439
        • Pfizer Investigational Site
    • Pennsylvania
      • Allentown、Pennsylvania、アメリカ、18106
        • Pfizer Investigational Site
      • Allentown、Pennsylvania、アメリカ、18103
        • Pfizer Investigational Site
      • Pittsburgh、Pennsylvania、アメリカ、15212
        • Pfizer Investigational Site
      • Pittsburgh、Pennsylvania、アメリカ、15213-3180
        • Pfizer Investigational Site
    • Rhode Island
      • East Providence、Rhode Island、アメリカ、02914
        • Pfizer Investigational Site
    • South Carolina
      • Charleston、South Carolina、アメリカ、29425
        • Pfizer Investigational Site
      • Columbia、South Carolina、アメリカ、29201
        • Pfizer Investigational Site
    • Tennessee
      • Kingsport、Tennessee、アメリカ、37660
        • Pfizer Investigational Site
      • Milan、Tennessee、アメリカ、38358
        • Pfizer Investigational Site
    • Texas
      • Houston、Texas、アメリカ、77024
        • Pfizer Investigational Site
    • Utah
      • Provo、Utah、アメリカ、84604
        • Pfizer Investigational Site
    • Virginia
      • Chesapeake、Virginia、アメリカ、23320
        • Pfizer Investigational Site
    • Washington
      • Seattle、Washington、アメリカ、98104
        • Pfizer Investigational Site
    • Wisconsin
      • Menomonee Falls、Wisconsin、アメリカ、53051
        • Pfizer Investigational Site
      • Latina、イタリア、04100
        • Pfizer Investigational Site
      • Padova、イタリア、35128
        • Pfizer Investigational Site
      • Siena、イタリア、53100
        • Pfizer Investigational Site
    • Andhra Pradesh
      • Hyderabad、Andhra Pradesh、インド、500 001
        • Pfizer Investigational Site
      • Hyderabad、Andhra Pradesh、インド、500 082
        • Pfizer Investigational Site
    • Karnataka
      • Bangalore、Karnataka、インド、560 034
        • Pfizer Investigational Site
    • Rajasthan
      • Jaipur、Rajasthan、インド、302 004
        • Pfizer Investigational Site
    • Tamil Nadu
      • Vellore、Tamil Nadu、インド、632 004
        • Pfizer Investigational Site
    • Uttar Pradesh
      • Lucknow、Uttar Pradesh、インド、226003
        • Pfizer Investigational Site
      • Chernivtsi、ウクライナ、58002
        • Pfizer Investigational Site
      • Kharkiv、ウクライナ、61037
        • Pfizer Investigational Site
      • Kyiv、ウクライナ、04053
        • Pfizer Investigational Site
      • Odessa、ウクライナ、65000
        • Pfizer Investigational Site
      • Zaporizhzhia、ウクライナ、69000
        • Pfizer Investigational Site
    • Alberta
      • Calgary、Alberta、カナダ、T2V 4R6
        • Pfizer Investigational Site
      • Edmonton、Alberta、カナダ、T5H 3V9
        • Pfizer Investigational Site
    • British Columbia
      • Victoria、British Columbia、カナダ、V8V 3N1
        • Pfizer Investigational Site
    • New Brunswick
      • Saint John、New Brunswick、カナダ、E2L 3J8
        • Pfizer Investigational Site
    • Ontario
      • Kitchener、Ontario、カナダ、N2N 2B9
        • Pfizer Investigational Site
      • Toronto、Ontario、カナダ、M4N 3M5
        • Pfizer Investigational Site
      • Toronto、Ontario、カナダ、M6A 3B5
        • Pfizer Investigational Site
    • Quebec
      • Montreal、Quebec、カナダ、H2X 1N8
        • Pfizer Investigational Site
      • Montreal、Quebec、カナダ、H3S 1Z1
        • Pfizer Investigational Site
      • Montréal、Quebec、カナダ、H2X 3J4
        • Pfizer Investigational Site
      • Sherbrooke、Quebec、カナダ、J1H 5N4
        • Pfizer Investigational Site
      • Rio, Patras、ギリシャ、26500
        • Pfizer Investigational Site
      • Thessaloniki、ギリシャ、56403
        • Pfizer Investigational Site
    • Attiki
      • Athens、Attiki、ギリシャ、10552
        • Pfizer Investigational Site
    • Ipiros
      • Ioannina、Ipiros、ギリシャ、45001
        • Pfizer Investigational Site
      • Alajuela、コスタリカ
        • Pfizer Investigational Site
      • Cartago、コスタリカ
        • Pfizer Investigational Site
      • San Jose、コスタリカ
        • Pfizer Investigational Site
    • Cundinamarca
      • Bogota、Cundinamarca、コロンビア
        • Pfizer Investigational Site
      • Bogota、Cundinamarca、コロンビア
        • Pfizer Investigational Site
      • Singapore、シンガポール、119074
        • Pfizer Investigational Site
      • Singapore、シンガポール、229899
        • Pfizer Investigational Site
      • Frauenfeld、スイス、CH-8500
        • Pfizer Investigational Site
      • Luzern 16、スイス、CH-6000
        • Pfizer Investigational Site
      • Huskvarna、スウェーデン、561 36
        • Pfizer Investigational Site
      • Lulea、スウェーデン、97180
        • Pfizer Investigational Site
      • Malmo、スウェーデン、205 02
        • Pfizer Investigational Site
      • Skovde、スウェーデン、541 30
        • Pfizer Investigational Site
      • Stockholm、スウェーデン
        • Pfizer Investigational Site
      • Madrid、スペイン、28046
        • Pfizer Investigational Site
      • Valencia、スペイン、46010
        • Pfizer Investigational Site
    • Madrid
      • Getafe、Madrid、スペイン、28905
        • Pfizer Investigational Site
    • Vizcaya
      • Bilbao、Vizcaya、スペイン、48013
        • Pfizer Investigational Site
      • Hradec Kralove、チェコ共和国、500 02
        • Pfizer Investigational Site
      • Jablonec nad Nisou、チェコ共和国、466 60
        • Pfizer Investigational Site
      • Jindrichuv Hradec、チェコ共和国、377 38
        • Pfizer Investigational Site
      • Ostrava、チェコ共和国、708 52
        • Pfizer Investigational Site
      • Praha 8、チェコ共和国、180 00
        • Pfizer Investigational Site
      • Puerto Montt、チリ、5480000
        • Pfizer Investigational Site
      • Santiago、チリ
        • Pfizer Investigational Site
    • VI Región
      • Rancagua、VI Región、チリ、2820945
        • Pfizer Investigational Site
      • Aalborg、デンマーク、9100
        • Pfizer Investigational Site
      • Aarhus N、デンマーク、8200
        • Pfizer Investigational Site
      • Glostrup、デンマーク、2600
        • Pfizer Investigational Site
      • Herlev、デンマーク、2730
        • Pfizer Investigational Site
      • Kolding、デンマーク、6000
        • Pfizer Investigational Site
      • Nykoebing Falster、デンマーク、4800
        • Pfizer Investigational Site
      • Roskilde、デンマーク、4000
        • Pfizer Investigational Site
      • Ahaus、ドイツ、41683
        • Pfizer Investigational Site
      • Alzey、ドイツ、55232
        • Pfizer Investigational Site
      • Berlin、ドイツ、10787
        • Pfizer Investigational Site
      • Berlin、ドイツ、13125
        • Pfizer Investigational Site
      • Berlin、ドイツ、13347
        • Pfizer Investigational Site
      • Karlsruhe、ドイツ、76199
        • Pfizer Investigational Site
      • Krumbach、ドイツ、86381
        • Pfizer Investigational Site
      • Leipzig、ドイツ、04109
        • Pfizer Investigational Site
      • Leipzig、ドイツ、04105
        • Pfizer Investigational Site
      • Marburg、ドイツ、35039
        • Pfizer Investigational Site
      • Muelheim a.d. Ruhr、ドイツ、45468
        • Pfizer Investigational Site
      • Muenchen、ドイツ、81241
        • Pfizer Investigational Site
      • Muenchen、ドイツ、81925
        • Pfizer Investigational Site
      • Rosenheim、ドイツ、83022
        • Pfizer Investigational Site
      • Bergen、ノルウェー、5005
        • Pfizer Investigational Site
      • Hamar、ノルウェー、2317
        • Pfizer Investigational Site
      • Lysaker、ノルウェー、1366
        • Pfizer Investigational Site
      • Oslo、ノルウェー、NO-0257
        • Pfizer Investigational Site
      • Oslo、ノルウェー、0264
        • Pfizer Investigational Site
      • Sandnes、ノルウェー、4313
        • Pfizer Investigational Site
      • Debrecen、ハンガリー、4026
        • Pfizer Investigational Site
      • Nyiregyhaza、ハンガリー、4400
        • Pfizer Investigational Site
      • Szeged、ハンガリー、6725
        • Pfizer Investigational Site
      • Szentes、ハンガリー、6600
        • Pfizer Investigational Site
    • BA
      • Salvador、BA、ブラジル、40420-000
        • Pfizer Investigational Site
    • RJ
      • Rio de Janeiro、RJ、ブラジル、CEP 20551-030
        • Pfizer Investigational Site
    • RS
      • Porto Alegre、RS、ブラジル、90020-090
        • Pfizer Investigational Site
      • Porto Alegre、RS、ブラジル、90470-340
        • Pfizer Investigational Site
    • SP
      • Campinas、SP、ブラジル、13084-882
        • Pfizer Investigational Site
      • São Paulo、SP、ブラジル、04262-000
        • Pfizer Investigational Site
      • São Paulo、SP、ブラジル、04039-901
        • Pfizer Investigational Site
      • Antwerpen、ベルギー、2020
        • Pfizer Investigational Site
      • Bruxelles、ベルギー、1070
        • Pfizer Investigational Site
      • Kortrijk、ベルギー、8500
        • Pfizer Investigational Site
      • Tessenderlo、ベルギー、3980
        • Pfizer Investigational Site
      • Lima、ペルー、L27
        • Pfizer Investigational Site
    • Lima
      • Surco、Lima、ペルー、L33
        • Pfizer Investigational Site
      • Bialystok、ポーランド、15-950
        • Pfizer Investigational Site
      • Bydgoszcz、ポーランド、85-168
        • Pfizer Investigational Site
      • Lodz、ポーランド、91-463
        • Pfizer Investigational Site
      • Szczecin、ポーランド、70-11
        • Pfizer Investigational Site
      • Warszawa、ポーランド、02-507
        • Pfizer Investigational Site
      • Kuala Lumpur、マレーシア、59100
        • Pfizer Investigational Site
    • Selangor
      • Batu Caves、Selangor、マレーシア、68100
        • Pfizer Investigational Site
      • Arad、ルーマニア、310175
        • Pfizer Investigational Site
      • Bucuresti、ルーマニア、041345
        • Pfizer Investigational Site
      • Bucuresti、ルーマニア、050653
        • Pfizer Investigational Site
      • Sibiu、ルーマニア、550245
        • Pfizer Investigational Site
      • Timisoara、ルーマニア、300736
        • Pfizer Investigational Site
      • Moscow、ロシア連邦、101000
        • Pfizer Investigational Site
      • Moscow、ロシア連邦、115516
        • Pfizer Investigational Site
      • Moscow、ロシア連邦、117815
        • Pfizer Investigational Site
      • Rostov-on-Don、ロシア連邦、344022
        • Pfizer Investigational Site
    • Russia
      • Moscow、Russia、ロシア連邦、105425
        • Pfizer Investigational Site
      • St. Petersburg、Russia、ロシア連邦
        • Pfizer Investigational Site
      • Cape Town、南アフリカ、8001
        • Pfizer Investigational Site
      • Pretoria、南アフリカ、0083
        • Pfizer Investigational Site
    • Free State
      • Bloemfontein、Free State、南アフリカ、9300
        • Pfizer Investigational Site
    • Gauteng
      • Vosloorus、Gauteng、南アフリカ、1475
        • Pfizer Investigational Site
    • Gauteng Province
      • Parktown、Gauteng Province、南アフリカ、2193
        • Pfizer Investigational Site
    • Kwa Zulu Natal
      • Durban、Kwa Zulu Natal、南アフリカ、4001
        • Pfizer Investigational Site
      • Pietermaritzburg、Kwa Zulu Natal、南アフリカ、3201
        • Pfizer Investigational Site
      • Hualien、台湾、970
        • Pfizer Investigational Site
      • Taichung City、台湾、40705
        • Pfizer Investigational Site
      • Taipei、台湾、100
        • Pfizer Investigational Site
      • Taipei、台湾
        • Pfizer Investigational Site
    • Kaohsiung
      • Niao-Sung Hsiang、Kaohsiung、台湾、833
        • Pfizer Investigational Site
      • Daegu、大韓民国、705-718
        • Pfizer Investigational Site
      • Seoul、大韓民国、120-752
        • Pfizer Investigational Site
      • Seoul、大韓民国、136-705
        • Pfizer Investigational Site
      • Seoul、大韓民国、137-040
        • Pfizer Investigational Site
      • Seoul、大韓民国、100-380
        • Pfizer Investigational Site
    • Korea
      • Seoul、Korea、大韓民国、110-744
        • Pfizer Investigational Site
      • Hong Kong、香港
        • Pfizer Investigational Site
      • Shatin、香港
        • Pfizer Investigational Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Adult overactive bladder (OAB) patients who present with OAB symptoms, including urinary frequency >= 8 per day and urgency urinary incontinence >=1 per day

Exclusion Criteria:

  • Patients with conditions that would contraindicate for fesoterodine use, e.g, hypersensitivity to the active substance (fesoterodine) or to peanut or soya or any of the excipients, urinary retention, and gastric retention.
  • Patients with significant hepatic and renal disease or other significant unstable diseases.
  • OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:フェソテロジン
タブレット
4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
プラセボコンパレーター:Placebo
Tablets and capsules
once daily (OD)for 12 weeks
アクティブコンパレータ:Tolterodine
Capsules
4 mg once daily (OD) for 12 weeks

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment).
時間枠:Baseline, Week 12
UUI per 24 hours: total number of micturitions with Urinary Sensation Scale (USS) of 5 divided by total number of diary days collected at visit. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Change: mean at observation minus mean at baseline.
Baseline, Week 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Change From Baseline in Mean Number of UUI Episodes Per 24 Hours at Week 1 and Week 4.
時間枠:Baseline, Week 1, Week 4
UUI episodes per 24 hours calculated as total number of micturitions with Urinary Sensation Scale (USS) of 5 divided by total number of diary days collected at visit. USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Change calculated as mean at observation minus mean at baseline.
Baseline, Week 1, Week 4
Percent Change From Baseline of UUI Episodes Per 24 Hours.
時間枠:Baseline, Week 1, Week 4, Week 12
UUI episodes per 24 hours calculated as total number of micturitions with USS of 5 in diary. USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Change calculated as UUI episodes per 24 hours at observation divided by baseline number of UUI episodes per 24 hours, multiplied by 100.
Baseline, Week 1, Week 4, Week 12
Change From Baseline in Mean Voided Volume Per Micturition.
時間枠:Baseline, Week 1, Week 4, Week 12
Mean voided volume calculated as sum of voided volume divided by the total number of micturition episodes with a recorded voided volume greater than 0 in the 3-day diary at that visit.
Baseline, Week 1, Week 4, Week 12
Change From Baseline in Mean Number of Micturitions Per 24 Hours.
時間枠:Baseline, Week 1, Week 4, Week 12
The mean number of micturitions was calculated as the sum of all micturitions divided by the total number of diary days collected at that visit. Change calculated as mean at observation minus mean at baseline.
Baseline, Week 1, Week 4, Week 12
Percent Change From Baseline of Micturitions Per 24 Hours.
時間枠:Baseline, Week 1, Week 4, Week 12
Percent change of micturitions per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (ie, 100% *(Week 12 or 4 - baseline)/baseline).
Baseline, Week 1, Week 4, Week 12
Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours.
時間枠:Baseline, Week 1, Week 4, Week 12
Mean number of nocturnal micturitions per 24 hours was calculated as the sum of all micturitions divided by the total number of diary days collected at that visit. Nocturnal (Bedtime) was defined as the time the subject went to bed until he/she arose to start the next day.
Baseline, Week 1, Week 4, Week 12
Percent Change From Baseline of Nocturnal Micturitions Per 24 Hours.
時間枠:Baseline, Week 1, Week 4, Week 12
Percent change of nocturnal micturitions per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (ie, 100% *(Week 12 or 4 - baseline)/baseline). Nocturnal (Bedtime) was defined as the time the subject went to bed until he/she arose to start the next day.
Baseline, Week 1, Week 4, Week 12
Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours.
時間枠:Baseline, Week 1, Week 4, Week 12
Mean number urgency episodes (USS rating >= to 3 in diary) per 24 hours calculated as sum of all micturitions divided by total number of diary days collected at visit. USS: 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Change calculated as mean at observation minus mean at baseline.
Baseline, Week 1, Week 4, Week 12
Percent Change From Baseline of Urgency Episodes Per 24 Hours.
時間枠:Baseline, Week 1, Week 4, Week 12
Percent change of urgency episodes (USS rating >= to 3 in diary) per 24 hours calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100. USS: 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Baseline, Week 1, Week 4, Week 12
Change From Baseline in Mean Number of Severe Urgency Episodes Per 24 Hours.
時間枠:Baseline, Week 1, Week 4, Week 12
Mean number of severe urgency episodes (USS rating >= to 4 in diary ) per 24 hours: sum of all micturitions divided by total number of diary days collected at that visit. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Change calculated as mean at observation minus mean at baseline.
Baseline, Week 1, Week 4, Week 12
Percent Change From Baseline of Severe Urgency Episodes Per 24 Hours.
時間枠:Baseline, Week 1, Week 4, Week 12
Percent change calculated as change in severe urgency episodes (USS rating >= to 4 in diary ) per 24 hours at that visit divided by the baseline number of severe urgency episodes per 24 hours, multiplied by 100. USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Baseline, Week 1, Week 4, Week 12
Change From Baseline in Mean USS Rating Per Micturition Per 24 Hours.
時間枠:Baseline, Week 1, Week 4, Week 12
Mean USS rating calculated as the sum of rating scores on USS per 24 hours divided by the mean number of micturitions per 24 hours at that visit. USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Change calculated as mean at observation minus mean at baseline.
Baseline, Week 1, Week 4, Week 12
Change From Baseline in Frequency-Urgency Sum (Formerly Known as Urinary Sensations Scale Sum in Protocol) Per 24 Hours.
時間枠:Baseline, Week 1, Week 4, Week 12
Frequency-Urgency Sum rating per 24 hours calculated as mean rating scores on the USS multiplied by the mean number of micturitions per 24 hours at that visit. USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Change calculated as mean at observation minus mean at baseline.
Baseline, Week 1, Week 4, Week 12
Change From Baseline in Patient Perception of Bladder Condition (PPBC).
時間枠:Baseline, Week 1, Week, 4, Week 12
Number of subjects in 4-point category: >= to 2 points improvement [major improvement]; 1 point improvement [minor improvement]; no change; deterioration, based on PPBC score (rated on 6-point scale: 1=no problems at all; 6=many severe problems). Score change: score at observation minus score at baseline; re-scaled to 4-point categorical variables.
Baseline, Week 1, Week, 4, Week 12
Change From Baseline in Urgency Perception Scale (UPS). UPS Equals Patient Perception of Urgency Scale (PPUS) in Protocol.
時間枠:Baseline, Week 1, Week 4, Week 12
Number of subjects in 3-point category: improvement [>=1-point improvement]; no change; deterioration [>=1-point decrease], based on UPS score (rated on 3-point scale: 1=not able to hold urine; 3=able to finish what I am doing). Score change calculated as score at observation minus score at baseline; re-scaled to 3-point categorical variables.
Baseline, Week 1, Week 4, Week 12
Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Symptom Bother Score at Week 12 (End of Treatment).
時間枠:Baseline, Week 12
Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48. Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score - lowest possible value of raw score)/by raw score range * 100]. Higher transformed scores indicative of greater symptom bother. Negative change in Symptom Bother score indicates improvement. Change calculated as score at observation minus score at baseline.
Baseline, Week 12
Change From Baseline in OAB-q: Health Related Quality of Life (HRQL) at Week 12 (End of Treatment).
時間枠:Baseline, Week 12
HRQL domain and total raw score derived as sum of scores (6-point scale: 1=not at all/none of the time; 6=a very great deal/all of the time). Transformed score (Total HRQL or domain)=[(Highest possible raw score-Actual total raw score)/Raw score range]x100. Higher transformed scores indicative of better HRQL. Positive change in HRQL scores indicates improvement. Change: score at observation minus score at baseline.
Baseline, Week 12

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2007年4月1日

一次修了 (実際)

2008年7月1日

研究の完了 (実際)

2008年7月1日

試験登録日

最初に提出

2007年3月6日

QC基準を満たした最初の提出物

2007年3月7日

最初の投稿 (見積もり)

2007年3月8日

学習記録の更新

投稿された最後の更新 (見積もり)

2015年3月24日

QC基準を満たした最後の更新が送信されました

2015年3月4日

最終確認日

2015年3月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する